Semaglutide for weight loss is a long-term prescription option, not a quick course or a replacement for food and activity changes. In the pivotal STEP 1 trial, participants receiving once-weekly semaglutide plus lifestyle support lost an average 14.9% of their starting weight at 68 weeks, compared with 2.4% on placebo plus the same support. That is a group average, not a forecast for one person.
The medication activates GLP-1 receptors involved in appetite and food intake. In practical terms, treatment means a repeating routine, gradual dose decisions made by a prescriber, and enough time to judge response over months rather than days.
Who was semaglutide for weight loss studied in?
STEP 1 enrolled 1,961 adults who did not have diabetes. Participants had a body mass index (BMI) of at least 30, or a BMI of at least 27 plus one or more weight-related conditions. They were randomized to semaglutide or placebo, and both groups received lifestyle intervention. Those numbers were the trial's entry criteria, not Promise's qualification rule.
At week 68, mean weight change was −14.9% with semaglutide and −2.4% with placebo, a difference of 12.4 percentage points (Wilding et al., New England Journal of Medicine 2021). The semaglutide weight-loss results guide puts that headline result into a week-by-week context without turning an average into a promise.
The trial tells us what happened in a defined population under controlled conditions. It does not establish that everyone above a particular BMI should receive semaglutide, or that someone outside those criteria cannot be considered. Medical history, current medicines, pregnancy plans, prior treatment, and contraindications all affect a prescriber's decision.
Wegovy, Ozempic, and compounded semaglutide
Semaglutide is the molecule; Wegovy and Ozempic are brand products with different labels. As of September 2026, the current Wegovy prescribing information includes long-term weight reduction for adults with obesity, or adults with overweight plus a weight-related condition. It also includes other indications. The current Ozempic prescribing information centers on adults with type 2 diabetes, including specified cardiovascular and kidney outcomes.
The shared molecule does not make the products interchangeable. Their labeled uses, delivery formats, strengths, and directions differ. Current U.S. labeling includes once-weekly injection and once-daily tablet Wegovy presentations, as well as once-weekly injection and once-daily tablet Ozempic presentations. A prescriber decides which product and formulation fit the patient rather than substituting one set of directions for another.
Promise's semaglutide is dispensed as a compounded medication, which is different from the FDA-approved Wegovy product: the formulation offered here is not FDA-approved. The FDA's compounding law summary explains that compounded drugs do not undergo the agency's premarket review for safety, effectiveness, or quality. Regulatory status is one input into treatment choice, and a licensed provider may still prescribe a compounded formulation when appropriate; that decision belongs to the patient and provider.
What weekly treatment actually involves
For an injectable prescription, the repeating unit is one week. The medication is administered subcutaneously on a schedule, while dose changes happen gradually. The prescriber sets the actual dose and pace based on the prescribed product, response, tolerability, medical history, and other medications. The semaglutide dosage schedule explains that titration in detail.
Week to week, the work is less dramatic than the marketing around GLP-1 medications suggests. It usually includes keeping the administration day consistent, noticing changes in hunger and fullness, maintaining hydration and regular meals, and reporting concerns to the clinical team. Weight can move unevenly even when the routine is consistent, so a single weigh-in says less than the trend across several weeks.
Follow-up matters because the dose that appears on a published label or in a trial is not automatically the right dose for an individual. A provider may hold a dose longer, change the plan, or decide that semaglutide is not the best fit. Tirzepatide may come up as a separate option because it acts at both GIP and GLP-1 receptors, but it is not a dose-for-dose substitute and needs its own clinical review.
Why diet and activity remain part of the treatment
STEP 1 did not test an injection in isolation. Both groups received lifestyle intervention, which means the 12.4-point difference estimates what semaglutide added to that shared foundation. The current Wegovy label likewise pairs the medication with a reduced-calorie diet and increased physical activity.
That pairing is not a moral test. Appetite biology, medication response, sleep, stress, mobility, food access, and other health conditions all shape what is realistic. The point is narrower: the evidence for semaglutide for weight loss comes from treatment programs in which food and movement remained active parts of care. Medication may support those changes; it does not make nutrition or physical activity irrelevant.
What happens when treatment stops?
Semaglutide is generally approached as ongoing care because its appetite-related effects do not necessarily persist after the medication leaves the body. In the STEP 1 extension, 327 participants were followed for one year after treatment and lifestyle support stopped. Those previously assigned semaglutide regained about two-thirds of their prior weight loss on average (Wilding et al., Diabetes, Obesity and Metabolism 2022).
That finding does not mean everyone follows the same path. It does mean stopping is a treatment decision, not simply the end of a short course. What happens when semaglutide is stopped covers the withdrawal evidence and planning questions in depth. Tolerability can also shape whether treatment continues; the dedicated semaglutide side-effects guide covers that subject without reducing it to a checklist here.
At Promise, a licensed provider reviews every request and prescribes only when semaglutide is appropriate; not everyone qualifies. A useful treatment plan is the one that accounts for the right product, a realistic weekly routine, the supporting habits used in the trials, and what long-term continuation would mean for that individual.